LLY Ticker Curator

• Full Termination: Lilly notified Rigel on April 16 to end the remaining RIPK1 inhibitor deal, effective June 15.
• Asset Details: Covered...

A $50 stock with stagnant earnings can be far more expensive than $900 LLY whose earnings grow by double-digit percentages in 2026. Price alone misleads—growth is the real valuation math.

Eli Lilly's innovative manufacturing strategy ensures rapid, standardized global expansion:

• $55B+ committed globally since 2020, with >$50B in U.S....

Local opposition mounts to Eli Lilly's $3.5B Upper Macungie plant incentives:

• Board majority resists 10-year LERTA tax abatement, citing economic...

Eli Lilly terminates collaboration with Rigel Pharmaceuticals, a low-impact adjustment as the RIPK1 deal ends without milestones.

Post-earnings optimism surges for Eli Lilly with Strong Buy consensus and avg PT of $1247.71 (34.6% upside).

• Guggenheim PT hike follows Q4 beat:...

Pipeline trim: Lilly terminates Rigel alliance effective June 15, handing back rights to two investigational RIPK1 inhibitors and ending milestone...

Insurer uncertainty clouds obesity drug coverage expansion:

• UnitedHealth highlights 'notable challenges' in Balance program's structure, in active...

FDA grants speedy approval to Eli Lilly's orforglipron obesity pill. In a trial of over 3,000 adults, the top 36mg dose delivered 11.2% body weight loss—milestone for LLY's oral GLP-1 pipeline.

Guggenheim raised its Eli Lilly (LLY) price target to $1,183 from $1,163 while maintaining a Buy rating, citing model updates.

Stock Pressure from Medicare Coverage Uncertainty

• 🔥 LLY Stock Slips 2.5%: Eli Lilly stock slipped 2.5% through 10:15 a.m. ET Tuesday despite...

Eli Lilly will terminate its RIPK1 License and Collaboration Agreement with Rigel, effective June 15, 2026, ending expected milestone and royalty payments.

Strategic oncology expansion: Eli Lilly acquires CrossBridge Bio's dual-payload ADC platform, originally from UTHealth Houston, to advance precise...

Eli Lilly vaulted from 10th place to the top spot in global pharmaceutical sales rankings for 2025, rewriting the industry hierarchy.

Eli Lilly and Novo face a guidance reset: narrowed Medicare access slams the path to massive, government-driven patient volume growth, pushing reliance on other avenues.

• Analyst bullish: Oliver Rodzianko upgrades LLY to Buy, citing sustained growth in obesity drug portfolio
• Market shrugs: LLY stock slips 2.5%...

Oral GLP-1 battle heats up: Lilly's Foundayo shows strong start with 1,390 prescriptions in first week (Apr 6), beating injected Zepbound (1,100) and...

Eli Lilly (LLY) confronts Medicare coverage hurdles for its weight drug Weig, even with a $800.74B market cap and strong positioning in innovative healthcare treatments.

Eli Lilly has a new Schedule 13G/A filing (0000316011-26-000011) from investors, signaling updates to passive institutional ownership.

Eli Lilly shares slipped more than 2% to 900.52 as CVS and Amazon chipped away at stocks, with Novo Nordisk down over 3% to 39.07. Viking Therapeutics (VKTX), a looming contender, noted amid the pressure.